Compare Lupin Ltd with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs ASTRAZENECA PHARMA - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN ASTRAZENECA PHARMA LUPIN/
ASTRAZENECA PHARMA
 
P/E (TTM) x -133.1 110.0 - View Chart
P/BV x 3.0 32.2 9.2% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 LUPIN   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    LUPIN
Mar-19
ASTRAZENECA PHARMA
Mar-18
LUPIN/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs9861,278 77.2%   
Low Rs720883 81.6%   
Sales per share (Unadj.) Rs369.5228.4 161.8%  
Earnings per share (Unadj.) Rs13.410.4 129.3%  
Cash flow per share (Unadj.) Rs37.416.3 229.9%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs303.798.8 307.5%  
Shares outstanding (eoy) m452.4925.00 1,810.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.34.7 48.8%   
Avg P/E ratio x63.6104.2 61.1%  
P/CF ratio (eoy) x22.866.4 34.4%  
Price / Book Value ratio x2.810.9 25.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m386,06427,008 1,429.5%   
No. of employees `00017.71.4 1,304.1%   
Total wages/salary Rs m31,5131,535 2,052.6%   
Avg. sales/employee Rs Th9,453.84,210.9 224.5%   
Avg. wages/employee Rs Th1,782.01,132.2 157.4%   
Avg. net profit/employee Rs Th343.0191.1 179.5%   
INCOME DATA
Net Sales Rs m167,1825,710 2,927.9%  
Other income Rs m3,640123 2,971.6%   
Total revenues Rs m170,8225,833 2,928.8%   
Gross profit Rs m28,822463 6,226.4%  
Depreciation Rs m10,850147 7,361.0%   
Interest Rs m3,0780-   
Profit before tax Rs m18,534438 4,231.5%   
Minority Interest Rs m-890-   
Prior Period Items Rs m380-   
Extraordinary Inc (Exp) Rs m-3,4000-   
Tax Rs m9,017179 5,040.2%   
Profit after tax Rs m6,066259 2,341.0%  
Gross profit margin %17.28.1 212.7%  
Effective tax rate %48.740.8 119.1%   
Net profit margin %3.64.5 80.0%  
BALANCE SHEET DATA
Current assets Rs m138,5363,209 4,316.8%   
Current liabilities Rs m61,2992,070 2,962.0%   
Net working cap to sales %46.220.0 231.5%  
Current ratio x2.31.6 145.7%  
Inventory Days Days8472 115.8%  
Debtors Days Days11235 322.0%  
Net fixed assets Rs m127,516790 16,135.1%   
Share capital Rs m90550 1,810.0%   
"Free" reserves Rs m136,5172,419 5,642.8%   
Net worth Rs m137,4222,469 5,565.2%   
Long term debt Rs m66,4170-   
Total assets Rs m279,4944,605 6,068.8%  
Interest coverage x7.0NM-  
Debt to equity ratio x0.50-  
Sales to assets ratio x0.61.2 48.2%   
Return on assets %3.35.6 58.2%  
Return on equity %4.410.5 42.1%  
Return on capital %8.917.7 50.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m59,414300 19,834.3%   
Fx outflow Rs m22,2822,015 1,105.9%   
Net fx Rs m37,132-1,715 -2,164.7%   
CASH FLOW
From Operations Rs m16,66088 18,953.0%  
From Investments Rs m-32,825-94 35,069.1%  
From Financial Activity Rs m7,441NA-  
Net Cashflow Rs m-8,724-6 153,047.4%  

Share Holding

Indian Promoters % 46.6 0.0 -  
Foreign collaborators % 0.2 75.0 0.3%  
Indian inst/Mut Fund % 11.3 0.3 3,766.7%  
FIIs % 31.9 15.7 203.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 9.1 111.0%  
Shareholders   98,259 12,856 764.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   WOCKHARDT  J.B.CHEMICALS  SHASUN PHARMA  BIOCON   FULFORD INDIA  

Compare LUPIN With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 307 Points Higher; Metal and Telecom Stocks Witness Buying(Closing)

Indian share markets traded on a positive note throughout the day and ended higher, tracking positive global sentiments.

Related Views on News

LUPIN Announces Quarterly Results (4QFY20); Net Profit Up 35.5% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, LUPIN has posted a net profit of Rs 4 bn (up 35.5% YoY). Sales on the other hand came in at Rs 38 bn (down 12.7% YoY). Read on for a complete analysis of LUPIN's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

6 Charts Showing the State of Indian Financial Markets in 2020(Sector Info)

May 26, 2020

Six charts showing how Indian financial markets have performed in 2020 so far...

Why We Picked This Smallcap Stock for a Post Coronavirus World(Profit Hunter)

May 28, 2020

Covid-19 has made it a survival of the fittest race for many companies. The ones that can adapt will thrive in a post crisis world.

What the RBI's Rate Cut Means for Options Traders(Fast Profits Daily)

May 25, 2020

The RBI governor has cut the repo rate to 4%. What does this mean for options traders? Find out in this video.

Who Will Be Crowned the 'Multibagger Blue Chip' of the Decade?(Profit Hunter)

May 25, 2020

Will the mutlibagger blue chips of the past decade continue to rule the bourses?

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Jun 5, 2020 (Close)

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS